Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Exclusion Criteria

• •Received radiotherapy, chemotherapy, surgery or other targeted and immunotherapy for triple-negative breast cancer before enrollment.
• •With heart disease classified as New York Heart Association class (NYHA) grade II or above (including grade II) are identified by the investigator.
• •With severe systemic infection or those with other serious illnesses.
• •Known to be allergic or intolerant to chemotherapy drugs or their excipients.
• •With a history of autoimmune diseases or those using glucocorticoids or immunosuppressive drugs.
• •With known active stage of HBV or HCV infection or hepatitis B DNA ≥500, or patients with chronic abnormal liver function.
• •With a history of abnormal thyroid function.
• •With grade ≥ 2 peripheral neuropathy.
• •With a clear history of neurological or mental disorders, including epilepsy or dement.
• •Previous non-breast malignancy within 5 years prior to study entry excluding healed cervical carcinoma in situ and non-melanoma skin cancer.
• •History of other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ and non-melanoma skin cancer.
• •Pregnancy or lactation, and patients of childbearing potential who refuse to use adequate contraception during the course of this study.
• •Prior participation in other studies within 30 days prior to the administration of the first dose of the investigational drug.
• •Patients who are deemed to be unsuitable for this study by investigators.